36 results about "Joint destruction" patented technology

The present invention discloses a novel compound and method for the treatment of inflammatory autoimmune diseases, for example, rheumatoid arthritis, using α-adrenergic antagonists and β-adrenergic agonists in combination. Treatment of animals, namely humans, with an α-adrenergic antagonist, preferably, phentolamine, and a β-adrenergic agonist, preferably terbutaline, in combination can significantly suppress the joint destruction and inflammation due to disease in these animals.

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl sulfonamides and related compounds (collectively referred to herein as ‘BPSAAA compounds’), as described herein, and including, for example, biphenyl-4-sulfonic acid (hydroxyalkyl-phenyl)-amides and related compounds. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment and/or prevention, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of, inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activation in rheumatoid arthritis, osteoporosis, cancer associated bone disease, Paget's disease and the like.

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc. Formula (I).

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as “APSAP compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc.

The invention discloses a device and a method for analyzing a joint destruction progress probability. The device comprises a parameter screening unit which is used for screening parameter variables for analyzing the joint destruction progress probability; a visual regression model generation unit which is used for constructing a column line graph by utilizing an R language according to the screened parameter variable data to obtain a visual regression model for analyzing the imaging joint damage progress risk probability of the rheumatoid arthritis patient; a data acquisition unit which is used for outputting each variable of the visual regression model obtained by the visual regression model generation unit through a graphical interface, providing data input and acquiring corresponding data input; And an analysis unit which is used for calculating the current input data by utilizing a visual regression model according to the obtained data of each variable to obtain a final analysis result, and the RA patient can intuitively analyze the joint damage progress risk probability in time and monitor the treatment effect of the disease.

The present invention relates to a method for eliciting a disease modifying effect on an arthritic condition in a mammal which comprises administering to the mammal a therapeutically effective amount of an anti-resorptive compound. The present invention also relates to method for eliciting a disease modifying effect on subchondral bone sclerosis, preventing osteophyte formation or progression and preventing joint destruction in a mammal which comprises administering to the mammal a therapeutically effective amount of an anti-resorptive compound.

The present invention relates to a method for eliciting a disease modifying effect on an arthritic condition in a hip or stifle of a canine which comprises administering to the canine a therapeutically effective amount of a bisphosphonate. The present invention also relates to method for eliciting a disease modifying effect on hip dysplasia or stifle instability, the pain associated with hip dysplasia or stifle instability, joint swelling, shallowing of the acetabulum, narrowing of the joint space, subchondral bone sclerosis, preventing osteophyte formation and preventing joint destruction in a canine which comprises administering to the canine a therapeutically effective amount of a bisphosphonate.

The invention belongs to the laser application technology field, relates to a test system and method for the joint destruction effect of laser and the surface airflow and aims to solve disadvantages of high cost, the huge size and the narrow application scope existing in a test system in the prior art. The test system for the joint destruction effect of the laser and the surface airflow comprisesa target, a beam module, an airflow simulation module and a monitoring device, wherein the beam module comprises a laser device and a first total reflective mirror, the first total reflective mirror is arranged on an emission light path of the laser device, the airflow simulation module comprises a motor and a supporting assembly fixedly connected with a motor rotation shaft, the first total reflective mirror, the target and the monitoring device are fixed at an upper end of the supporting assembly, the first total reflective mirror is arranged in the middle, the target and the monitoring device are arranged at two sides of the first total reflective mirror, the light emitted by the laser device is reflected by the first total reflective mirror to irradiate onto the target, and a light signal on the surface of the target enters the monitoring device and is not blocked by the first total reflective mirror.

The invention provides a system for analyzing rheumatoid arthritis (RA). The system according to the invention comprises a patient data acquisition module, a data input module and an analysis module,thereby understanding a joint destruction progress of an RA patient and monitoring the treatment effect of diseases in time. According to the system of the invention, a nuclear magnetic resonator utilizes a 3.0T whole-body scanning system realizes higher image resolution through increasing a signal-to-noise ratio by means of an eight-channel head coil. The average scanning time is only 24 minutes,thereby laying a solid basis for later clinical popularization.

Disclosed herein is a minimally invasive ball joint implant and prosthesis 10 for the treatment of arthritis, trauma, and other medical conditions leading to joint destruction and pain, as well as methods of use. In various cases, the prosthesis 10 does not require reaming into the intramedullary canal and does not require diaphyseal fit for any bones associated with the joint, thereby resulting in more rapid and complete recovery. In various cases, the prosthesis 10 incorporates an anchoring stem 38 specifically designed to be impacted into the bone and to facilitate bony ingrowth after implantation, thereby strengthening the implanted prosthesis 10 and preventing rotation thereof.

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and/or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as Behçet's disease. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

The present invention provides a suppressing agent for inflammatory cytokine expression in joints and/or joint destruction (e.g., articular cartilage destruction) and/or pain in a bone/joint disease, comprising a substance that suppresses the expression or activity of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence shown by SEQ ID NO:2, a screening method for a substance that regulates inflammatory cytokine expression in joints and/or joint destruction (e.g., articular cartilage destruction) and/or pain in a bone/joint disease, comprising using the protein or a partial peptide thereof, and a diagnostic method for genetic susceptibility to a bone/joint disease, comprising detecting a polymorph in the base shown by base number 24007 in the partial base sequence of the human EDG2 gene shown by SEQ ID NO:3.

The invention relates to an application of polygonum cuspidatum, polydatin and emodin in treatment of rheumatoid arthritis. In particular, the invention discloses polygonum cuspidatum, polydatin and emodin which can alleviate symptoms related to rheumatoid arthritis, such as arthralgia, swelling, morning stiffness and/or joint destruction.

Provided herein are methods of treating, delaying progression of, or reducing the severity of metabolic disorders characterized with increased COX-2 expression and/or PGE2 expression and/or EP4 expression in bone related cells through administration of an agent configured to inhibit and/or diminish COX-2 expression, and/or PGE2 expression, and/or EP4 expression in bone related cells. In some embodiments, such administration results in one or more of the following: inhibited or reduced COX-2 expression; inhibited or reduced PGE2 expression; inhibited or reduced EP4 expression; inhibited or reduced aberrant subchondral bone remodeling and/or innervation; inhibited or reduced cartilage degeneration; and inhibited or reduced joint destruction.

The present invention is methods for inhibiting collagen destruction in joints of osteoarthritis patients. The methods are based on use of rexinoid compounds, in particular bexarotene, and their activity to inhibit synthesis of matrix metalloproteinases (MMPs) in affected tissue.

The invention provides an agent for preventing or treating arthritis, a cartilage protecting agent, a joint destruction inhibitor and a synovial membrane growth inhibitor comprising an anti-FGF-8 neutralizing antibody as an active ingredient, as well as a diagnostic agent of arthritis comprising an anti-FGF-8 antibody as an active ingredient and a method for judging arthritis using the antibody.

The invention disclosed provides means of inhibiting, ameliorating, and/or treatment of rheumatoid arthritis through the use of Noble gas containing mixtures. In one embodiment, the invention provides means of reducing inflammation and immune associated pathology through administration of Noble gas mixtures. In one specific embodiment, Xenon gas is administered to a patient in need at concentrations and frequencies sufficient to inhibit inflammatory and autoimmune processes. In another embodiment Noble gas mixtures are administered to reduce pain and provide symptomatic relieve to a patient suffering from rheumatoid arthritis. In another embodiment the use of Noble gas containing mixtures is disclosed as a means of reducing joint destruction through inhibition of matrix metalloprotease production and activity.